Lead Product(s): N-Acetylcysteine,2,4-disulfonyl alpha-phenyl tertiary butyl nitrone
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 12, 2020
Oblato assumes exclusive rights to a drug known as NHPN-1010. Oblato is expected to initiate a phase 2 clinical trial to evaluate the potential of the drug to prevent and treat hearing loss.